Harvard Bioscience, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $8.6M | $4.1M | $4.3M | $4.5M | $7.8M | $8.3M | $8.3M | $8.2M |
| Accounts Receivable | $16.0M | $14.9M | $16.1M | $16.7M | $21.8M | $17.8M | $20.7M | $21.5M |
| Inventory | $20.8M | $23.2M | $24.7M | $26.4M | $27.6M | $22.3M | $22.1M | $25.1M |
| Total Current Assets | $48.2M | $45.1M | $49.0M | $51.1M | $61.6M | $51.7M | $53.6M | $57.8M |
| Property, Plant & Equipment | $4.8M | $5.1M | $4.0M | $3.4M | $3.4M | $4.0M | $4.8M | $5.9M |
| Goodwill | $9.6M | $56.3M | $57.1M | $56.3M | $57.7M | $58.6M | $57.4M | $57.3M |
| Intangible Assets (Excl. Goodwill) | $7.6M | $11.1M | $16.0M | $21.0M | $27.4M | $33.2M | $38.4M | $45.8M |
| Total Assets | $80.1M | $126.6M | $137.4M | $145.4M | $162.3M | $156.3M | $164.9M | $168.6M |
| Liabilities | ||||||||
| Accounts Payable | $3.7M | $4.8M | $5.6M | $6.4M | $4.9M | $6.0M | $5.3M | $7.4M |
| Total Current Liabilities | $22.0M | $55.0M | $26.5M | $23.2M | $25.3M | $21.1M | $25.3M | $25.5M |
| Long-Term Debt | $35.9M | $0 | $30.7M | $43.0M | $45.1M | $46.3M | $46.9M | $54.8M |
| Total Liabilities | $66.3M | $63.3M | $64.3M | $73.1M | $78.9M | $79.6M | $83.2M | $85.9M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-214.7M | $-158.0M | $-145.6M | $-142.2M | $-132.7M | $-132.4M | $-124.6M | $-119.9M |
| Total Stockholders' Equity | $13.7M | $63.3M | $73.1M | $72.2M | $83.4M | $76.7M | $81.7M | $82.7M |